Reduce ADC Conjugation Risk with Consistent Antibody Quality, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how consistent antibody quality can support efficient antibody-drug conjugate (ADC) manufacturing. The featured speaker will discuss antigen binding, structural stability, conjugation readiness and the role of upstream and downstream processes in maintaining antibody quality. Attendees will also explore how scale-up planning and process control can reduce variability and support more predictable ADC performance.

TORONTO, Sept. 3, 2026 /PRNewswire/ -- Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with potent cytotoxic payloads for targeted oncology. While an ADC consists of an antibody, linker and payload, the antibody provides the targeting capability needed for selective delivery to tumor cells. Its quality, consistency and stability are therefore critical to successful conjugation, downstream processing and final ADC performance.

This webinar will explore key development considerations for antibodies intended for ADC therapies, including antigen specificity, binding strength, structural stability and readiness for chemical conjugation. The discussion will examine why antibody molecules must maintain consistent quality attributes throughout development and manufacturing, especially as they move toward conjugation with potent payloads.

Participants will also learn how cell line development and upstream production processes affect antibody output and how downstream purification workflows help isolate the antibody and remove impurities before the molecule advances to payload attachment.

As ADC programs progress from early development toward clinical and commercial manufacturing, scale-up introduces additional requirements for reproducibility, process characterization and control of product quality attributes. The session will address how maintaining stable antibody quality during manufacturing scale-up can support efficient conjugation, reduce variability and contribute to more predictable final ADC performance.

A featured success story will illustrate how variability in antibody glycosylation patterns affected conjugation efficiency and how upstream process optimization improved consistency in antibody quality attributes and overall manufacturing performance.

The webinar will also highlight how experienced CDMO support can help development teams establish reliable antibody production processes, address quality variability and progress toward downstream conjugation and commercial readiness. Attendees will gain a clearer understanding of how antibody manufacturing and scale-up decisions affect ADC development and support targeted oncology programs.

Register for this webinar to learn how ADC manufacturing strategies can improve antibody consistency, support efficient conjugation and reduce scale-up risk.

Join Dave Briggs, PhD, MSAT Principal Scientist, Late Stage/Commercial, Avid Bioservices, for the live webinar on Thursday, September 24, 2026, at 12pm EDT (6pm CEST / EU-Central).

For more information, or to register for this event, visit Reduce ADC Conjugation Risk with Consistent Antibody Quality.

ABOUT XTALKS

Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.

To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: [email protected]

SOURCE Xtalks